These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26827608)

  • 1. Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach.
    Kumar DT; Doss CG
    Adv Protein Chem Struct Biol; 2016; 102():267-97. PubMed ID: 26827608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of E542 and E545 missense mutations of PIK3CA in breast cancer: a comparative computational approach.
    Thirumal Kumar D; George Priya Doss C
    J Biomol Struct Dyn; 2017 Sep; 35(12):2745-2757. PubMed ID: 27581627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA somatic mutations in breast cancer: Mechanistic insights from Langevin dynamics simulations.
    Mankoo PK; Sukumar S; Karchin R
    Proteins; 2009 May; 75(2):499-508. PubMed ID: 18951408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway.
    Zhou J; Imani S; Shasaltaneh MD; Liu S; Lu T; Fu J
    Mol Biol Rep; 2022 Mar; 49(3):1799-1816. PubMed ID: 34816327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deciphering the impact of somatic mutations in exon 20 and exon 9 of PIK3CA gene in breast tumors among Indian women through molecular dynamics approach.
    Sudhakar N; Priya Doss CG; Thirumal Kumar D; Chakraborty C; Anand K; Suresh M
    J Biomol Struct Dyn; 2016; 34(1):29-41. PubMed ID: 25679319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrated investigation of structural and pathway alteration caused by PIK3CA and TP53 mutations identified in cfDNA of metastatic breast cancer.
    R HC; Kumar S U; R G; Naayanan PJ; Sathiyarajeswaren P; Devi MSS; K SS; Doss C GP
    J Cell Biochem; 2023 Feb; 124(2):188-204. PubMed ID: 36563059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP.
    Menteş M; Karakuzulu BB; Uçar GB; Yandım C
    Comput Biol Chem; 2022 Aug; 99():107726. PubMed ID: 35842959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach.
    George Priya Doss C; Rajith B; Chakraboty C; Balaji V; Magesh R; Gowthami B; Menon S; Swati M; Trivedi M; Paul J; Vasan R; Das M
    Mol Biosyst; 2014 Mar; 10(3):421-36. PubMed ID: 24336963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.
    Ross RL; Askham JM; Knowles MA
    Oncogene; 2013 Feb; 32(6):768-76. PubMed ID: 22430209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomic and molecular docking studies on the cytotoxicity of the natural steroid wortmannin against multidrug-resistant tumor cells.
    Kuete V; Saeed ME; Kadioglu O; Börtzler J; Khalid H; Greten HJ; Efferth T
    Phytomedicine; 2015 Jan; 22(1):120-7. PubMed ID: 25636880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
    Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
    Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unraveling the Structural Changes in the DNA-Binding Region of Tumor Protein p53 (
    Balasundaram A; Doss CGP
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant.
    Gkeka P; Evangelidis T; Pavlaki M; Lazani V; Christoforidis S; Agianian B; Cournia Z
    PLoS Comput Biol; 2014 Oct; 10(10):e1003895. PubMed ID: 25340423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
    Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
    PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants.
    Ghodsinia AA; Lego JMT; Garcia RL
    Cells; 2020 Apr; 9(5):. PubMed ID: 32365913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer.
    Nichols AC; Palma DA; Chow W; Tan S; Rajakumar C; Rizzo G; Fung K; Kwan K; Wehrli B; Winquist E; Koropatnick J; Mymryk JS; Yoo J; Barrett JW
    JAMA Otolaryngol Head Neck Surg; 2013 Jun; 139(6):617-22. PubMed ID: 23787421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel method for PIK3CA mutation analysis: locked nucleic acid--PCR sequencing.
    Ang D; O'Gara R; Schilling A; Beadling C; Warrick A; Troxell ML; Corless CL
    J Mol Diagn; 2013 May; 15(3):312-8. PubMed ID: 23541593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of effective natural PIK3CA H1047R inhibitors by computational study.
    Liu N; Wang X; Li X; Lv X; Xie H; Guo Z; Wang J; Dou G; Du Y; Song D
    Aging (Albany NY); 2021 Aug; 13(16):20246-20257. PubMed ID: 34415239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
    Kehr EL; Jorns JM; Ang D; Warrick A; Neff T; Degnin M; Lewis R; Beadling C; Corless CL; Troxell ML
    Hum Pathol; 2012 Dec; 43(12):2207-12. PubMed ID: 22705004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural and dynamical aspects of Streptococcus gordonii FabH through molecular docking and MD simulations.
    Shamim A; Abbasi SW; Azam SS
    J Mol Graph Model; 2015 Jul; 60():180-96. PubMed ID: 26059477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.